Jaid, Farnisa J.
HRN: 49 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/13/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
07/13/2022
07/20/2022
IV
120mg
Q24H
PCAP-D
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes